

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal

Atezolizumab with cobimetinib and vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma ID1674

Provisional stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Roche (atezolizumab with cobimetinib and vemurafenib) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Black Health Agency • British Skin Foundation • Cancer Black Care • Cancer Equality • Cancer 52 • Helen Rollason Heal Cancer Charity • Macmillan Cancer Support • Maggie's Centres • Marie Curie • Melanoma UK • Muslim Council of Britain • Skcin - Karen Clifford Skin Cancer Charity • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • British Association of Dermatologists • British Association of Skin Cancer Specialist Nurses • British Association of Surgical Oncology • British Dermatological Nursing Group • British Geriatrics Society • British Institute of Radiology 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutic and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> • Array BioPharma and Pierre Fabre (encorafenib with binimetinib) • Bristol-Myers Squibb Pharmaceuticals (nivolumab and ipilimumab) • Merck Sharp & Dohme (pembrolizumab) • Novartis Pharmaceuticals (dabrafenib and trametinib) • Roche (vemurafenib)

Provisional stakeholder list for the technology appraisal of atezolizumab with cobimetinib and vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma ID1674

Issue date: October 2019

© National Institute for Health and Care Excellence 2019. All rights reserved. Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Psychosocial Oncology Society • British Skin Foundation • Cancer Research UK • Melanoma Focus • Primary Care Dermatology Society • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • United Kingdom Clinical Pharmacy Association • United Kingdom Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS Aylesbury Vale CCG • NHS England • NHS Southampton CCG • Welsh Government 	<p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Society for Dermatological Surgery • Cochrane Skin Group • Genomics England • Institute of Cancer Research • MRC Clinical Trials Unit • Melanoma Fund • National Cancer Research Institute • National Cancer Research Network • National Institute for Health Research • Skin Cancer Research Fund • Skin Treatment & Research Trust <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTees AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.